AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Study Identifier
201904-006
CT.gov Identifier
NCT00325715
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Other
    • Study Drug
  • AGN 201904
  • esomeprazole
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Healthy Adult Volunteers who have provided written informed consent
    Exclusion Criteria:
    * Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease. * Female volunteers who pregnant, nursing, or planning a pregnancy * Volunteers with a history of drug or alcohol abuse

    Protocol Summary

    AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

    Study Locations

    Location
    Status
    Location
    Houston, Texas, United States
    Status
    Not applicable